Carruthers Ross, Chalmers Anthony J
Institute of Cancer Sciences, University of Glasgow, Switchback Road, Bearsden, Glasgow G12 8QQ, UK.
CNS Oncol. 2012 Sep;1(1):85-97. doi: 10.2217/cns.12.13.
DNA damaging agents have an integral role in the treatment of brain tumors. Recent advances in our understanding of how cancer cells repair DNA damage have made it possible to consider modification of the DNA damage response as a way in which resistance to radiotherapy and chemotherapy might be overcome. PARP inhibitors are potent but nontoxic drugs that inhibit repair of DNA single-strand breaks and increase the cytotoxic effects of radiotherapy and alkylating chemotherapy agents, including temozolomide. PARP inhibitors have potential applications in neuro-oncology because there is increasing evidence that their radio- and chemo-sensitizing effects are tumor specific. This review explores the mechanisms of action of PARP inhibitors and describes their putative mechanisms of radio- and chemo-sensitization in the context of CNS oncology. The authors go on to review their development in recent clinical trials, with a focus on glioblastoma.
DNA损伤剂在脑肿瘤治疗中起着不可或缺的作用。近年来,我们对癌细胞如何修复DNA损伤的认识取得了进展,这使得将DNA损伤反应的调节视为克服放疗和化疗耐药性的一种方法成为可能。PARP抑制剂是一类强效但无毒的药物,可抑制DNA单链断裂的修复,并增强放疗和包括替莫唑胺在内的烷化化疗药物的细胞毒性作用。PARP抑制剂在神经肿瘤学中具有潜在应用价值,因为越来越多的证据表明它们的放射增敏和化学增敏作用具有肿瘤特异性。本文综述了PARP抑制剂的作用机制,并在中枢神经系统肿瘤学背景下描述了其假定的放射增敏和化学增敏机制。作者接着回顾了它们在近期临床试验中的进展,重点是胶质母细胞瘤。